pravastatin has been researched along with methylnitrosourea in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, R; Fukaura, Y; Hasebe, M; Ito, M; Morotomi, M; Narisawa, T | 1 |
| Adamicová, K; Adamkov, M; Bojková, B; Chmelová, M; Kajo, K; Kapinová, A; Kassayová, M; Kružliak, P; Kubatka, P; Orendáš, P; Péč, M; Sadloňová, V; Stollárová, N; Výbohová, D | 1 |
2 other study(ies) available for pravastatin and methylnitrosourea
| Article | Year |
|---|---|
Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.
Topics: Animals; Anticarcinogenic Agents; Bile Acids and Salts; Body Weight; Cholesterol; Colonic Neoplasms; Drinking; Eating; Enzyme Inhibitors; Feces; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Methylnitrosourea; Pravastatin; Rats; Rats, Inbred F344; Sterols | 1996 |
Melatonin potentiates the anti-tumour effect of pravastatin in rat mammary gland carcinoma model.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Disease Models, Animal; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mammary Neoplasms, Experimental; Melatonin; Methylnitrosourea; Pravastatin; Rats, Sprague-Dawley | 2014 |